Silverfin false false 31/03/2025 01/04/2024 31/03/2025 E L Burgess 25/07/2022 G Burgess 17/03/2016 Gary Burgess 07 October 2025 The principal activity of the Company during the financial year was that of clinical consulting. 10068396 2025-03-31 10068396 bus:Director1 2025-03-31 10068396 bus:Director2 2025-03-31 10068396 2024-03-31 10068396 core:CurrentFinancialInstruments 2025-03-31 10068396 core:CurrentFinancialInstruments 2024-03-31 10068396 core:ShareCapital 2025-03-31 10068396 core:ShareCapital 2024-03-31 10068396 core:RetainedEarningsAccumulatedLosses 2025-03-31 10068396 core:RetainedEarningsAccumulatedLosses 2024-03-31 10068396 core:ComputerEquipment 2024-03-31 10068396 core:ComputerEquipment 2025-03-31 10068396 2023-03-31 10068396 bus:OrdinaryShareClass1 2025-03-31 10068396 2024-04-01 2025-03-31 10068396 bus:FilletedAccounts 2024-04-01 2025-03-31 10068396 bus:SmallEntities 2024-04-01 2025-03-31 10068396 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 10068396 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 10068396 bus:Director1 2024-04-01 2025-03-31 10068396 bus:Director2 2024-04-01 2025-03-31 10068396 bus:Director3 2024-04-01 2025-03-31 10068396 core:ComputerEquipment core:TopRangeValue 2024-04-01 2025-03-31 10068396 2023-04-01 2024-03-31 10068396 core:ComputerEquipment 2024-04-01 2025-03-31 10068396 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 10068396 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 10068396 (England and Wales)

GCB CLINICAL CONSULTING LTD

Unaudited Financial Statements
For the financial year ended 31 March 2025
Pages for filing with the registrar

GCB CLINICAL CONSULTING LTD

Unaudited Financial Statements

For the financial year ended 31 March 2025

Contents

GCB CLINICAL CONSULTING LTD

STATEMENT OF FINANCIAL POSITION

As at 31 March 2025
GCB CLINICAL CONSULTING LTD

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 March 2025
Note 2025 2024
£ £
Fixed assets
Tangible assets 3 727 1,462
727 1,462
Current assets
Debtors 4 21,897 42,983
Cash at bank and in hand 427,710 365,319
449,607 408,302
Creditors: amounts falling due within one year 5 ( 48,484) ( 16,408)
Net current assets 401,123 391,894
Total assets less current liabilities 401,850 393,356
Provision for liabilities 6 ( 182) ( 366)
Net assets 401,668 392,990
Capital and reserves
Called-up share capital 7 100 100
Profit and loss account 401,568 392,890
Total shareholders' funds 401,668 392,990

For the financial year ending 31 March 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of GCB Clinical Consulting Ltd (registered number: 10068396) were approved and authorised for issue by the Board of Directors on 07 October 2025. They were signed on its behalf by:

Gary Burgess
Director
GCB CLINICAL CONSULTING LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025
GCB CLINICAL CONSULTING LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

GCB Clinical Consulting Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 5th Floor, Salt Quay House 4 North East Quay, Sutton Harbour, Plymouth, PL4 0BN, United Kingdom. The principal place of business is 1 Mount Road, Canterbury, Kent, CT1 1YD.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset over its expected useful life, as follows:

Computer equipment 4 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Statement of Financial Position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Tangible assets

Computer equipment Total
£ £
Cost
At 01 April 2024 3,846 3,846
At 31 March 2025 3,846 3,846
Accumulated depreciation
At 01 April 2024 2,384 2,384
Charge for the financial year 735 735
At 31 March 2025 3,119 3,119
Net book value
At 31 March 2025 727 727
At 31 March 2024 1,462 1,462

4. Debtors

2025 2024
£ £
Trade debtors 5,379 30,563
Amounts owed by directors 0 7,399
Prepayments and accrued income 14,021 5,021
Other debtors 2,497 0
21,897 42,983

5. Creditors: amounts falling due within one year

2025 2024
£ £
Accruals 3,200 3,200
Taxation and social security 45,284 13,208
48,484 16,408

6. Deferred tax

2025 2024
£ £
At the beginning of financial year ( 366) ( 606)
Credited to the Statement of Income and Retained Earnings 184 240
At the end of financial year ( 182) ( 366)

7. Called-up share capital

2025 2024
£ £
Allotted, called-up and fully-paid
100 Ordinary shares of £ 1.00 each 100 100

8. Related party transactions

Transactions with the entity's directors

2025 2024
£ £
Amounts owed by the directors to the company 0 7,399

During the year, the directors repaid a loan account with the company. Interest is charged on the loan at HMRC approved rates when overdrawn. There is no fixed date of repayment.